> ## Content Index > Fetch the complete content index at: https://www.whiteroseintelligence.com/llms.txt > Use this file to discover other available public pages before exploring further. # Brighton Collaboration - URL: https://www.whiteroseintelligence.com/brighton-collaboration/ - Published: 1999-01-02T12:15:00.000Z - Updated: 2025-01-01T03:15:50.000Z - Author: Liam Sturgess - Tags: Profiles, #docs, #organization The **Brighton Collaboration Foundation**, or simply the **Brighton Collaboration**, is a non-governmental organization based in Basel, Switzerland. It is a program under the Task Force for Global Health which provides administration services and support, including the management of all of the Collaboration’s donations and grants. ## History The Brighton Collaboration originated in 1999 and formed in 2000 to define safety parameters for vaccines, then collect and disseminate it to encourage vaccine uptake worldwide.[\[1\]](#fn1) In May 2019, Brighton and the [Coalition for Epidemic Preparedness Innovations](https://www.whiteroseintelligence.com/Coalition-for-Epidemic-Preparedness-Innovations) (CEPI) partnered to launch the Safety Platform for Emergency vACcines (SPEAC).[\[2\]](#fn2) ### COVID-19 In June 2020, Brighton published a report titled “[Priority List of Adverse Events of Special Interest: COVID-19](https://web.archive.org/web/20220901064833/https://brightoncollaboration.us/wp-content/uploads/2020/06/SPEAC%5FD2.3%5FV2.0%5FCOVID-19%5F20200525%5Fpublic.pdf).”[\[3\]](#fn3) It was updated several times up to [December 2020](https://web.archive.org/web/20230116101512/https://brightoncollaboration.us/wp-content/uploads/2021/01/SO2%5FD2.1.2%5FV1.2%5FCOVID-19%5FAESI-update-23Dec2020-review%5Ffinal.pdf). The report was commissioned by CEPI. #### Redefining anaphylaxis The Brighton Collaboration convened an "anaphylaxis working group" in June 2021 consisting of ten members in order to update and revise the definition of anaphylaxis.[\[4\]](#fn4) ## Organization The Brighton Collaboration is a program of the Task Force for Global Health. Currently, the primary funding for the Brighton Collaboration comes from the Coalition for Epidemic Preparedness Innovations (CEPI). It is a member of the [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization)'s Vaccine Safety Net, is partnered with the Vaccine Confidence Project,[\[5\]](#fn5) and is associated with HELP Eliminate Pain in Kids & Adults.[\[6\]](#fn6) ### Personnel | Name | Position | Notes | | -------------------- | ----------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------- | | Ananda Amarasinghe | Anaphylaxis Working Group member[\[4:1\]](#fn4) | WHO Regional Office for the Western Pacific | | Michael Gold | Anaphylaxis Working Group member | University of Adelaide Medical School | | Matthew Greenhawt | Anaphylaxis Working Group member | Children's Hospital Colorado, University of Colorado School of Medicine | | John Kelso | Anaphylaxis Working Group member | Scripps Clinic | | Sonali Kochhar | Anaphylaxis Working Group member | University of Washington Department of Global Health | | Bernard Yu-Hor Thong | Anaphylaxis Working Group member | Tan Tock Seng Hospital | | Karina Top | Anaphylaxis Working Group member | [Vaccine Surveillance Reference Group](https://www.whiteroseintelligence.com/Vaccine-Surveillance-Reference-Group) (VSRG), Dalhousie University | | Paul Turner | Anaphylaxis Working Group member | National Heart and Lung Institute, University of Sydney | | Margitta Worm | Anaphylaxis Working Group member | Charité – Berlin University Medicine | ## Activities The Brighton Collaboration has provided funding to the World Health Organization.[\[7\]](#fn7) ### Publications - April 21, 2021: [Interim Case Definition of Thrombosis with Thrombocytopenia Syndrome (TTS)](https://web.archive.org/web/20210421215120/https://brightoncollaboration.us/thrombosis-with-thrombocytopenia-syndrome-interim-case-definition/) **Priority List of Adverse Events of Special Interest: COVID-19** - [V2.0 - May 25, 2020](https://web.archive.org/web/20201130055354/https://brightoncollaboration.us/wp-content/uploads/2020/06/SPEAC%5FD2.3%5FV2.0%5FCOVID-19%5F20200525%5Fpublic.pdf) - [Quarterly update V1.2 - December 23, 2020](https://web.archive.org/web/20210224091155/https://brightoncollaboration.us/wp-content/uploads/2021/01/SO2%5FD2.1.2%5FV1.2%5FCOVID-19%5FAESI-update-23Dec2020-review%5Ffinal.pdf) ## External links - [Campfire Wiki](https://www.campfire.wiki/doku.php?id=brighton%5Fcollaboration) - [Website](https://brightoncollaboration.org/) - [Wikipedia](https://en.wikipedia.org/wiki/Brighton%5FCollaboration) ### Further reading - April 6, 2023: "[Anaphylaxis: Revision of the Brighton collaboration case definition](https://www.sciencedirect.com/science/article/pii/S0264410X22014256)," published in *Vaccine* --- 1. *About*. Brighton Collaboration. Retrieved April 19, 2022, from [↩︎](#fnref1) 2. *Safety Platform for Emergency vACcines (SPEAC).* (2019, May 9). Brighton Collaboration. [↩︎](#fnref2) 3. *Priority List of Adverse Events of Special Interest: COVID-19.* (2020, June 10). Brighton Collaboration. [↩︎](#fnref3) 4. Gold, M. S., Amarasinghe, A., Greenhawt, M., Kelso, J. M., Kochhar, S., Yu-Hor Thong, B., Top, K. A., Turner, P. J., Worm, M., & Law, B. (2022). Anaphylaxis: Revision of the Brighton collaboration case definition. *Vaccine, 41*(15). [↩︎](#fnref4) [↩︎](#fnref4:1) 5. *Partners & Funders.* Vaccine Confidence Project. Retrieved April 28, 2022, from [↩︎](#fnref5) 6. *Organizations & Groups (utilizing our work).* HELPinKids&Adults. Retrieved February 24, 2024, from [↩︎](#fnref6) 7. *Voluntary contributions by fund and by contributor, 2017.* (2018, April 19). World Health Organization. [↩︎](#fnref7)